2022
Diet- and Lifestyle‐Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance)
Cheng E, Ou FS, Ma C, Spiegelman D, Zhang S, Zhou X, Bainter TM, Saltz LB, Niedzwiecki D, Mayer RJ, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Giovannucci EL, Van Blarigan EL, Brown JC, Ng K, Gross CP, Meyerhardt JA, Fuchs CS. Diet- and Lifestyle‐Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). Journal Of Clinical Oncology 2022, 40: 740-751. PMID: 34995084, PMCID: PMC8887946, DOI: 10.1200/jco.21.01784.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantColonic NeoplasmsDietFemaleFollow-Up StudiesHumansLife StyleMaleMiddle AgedModels, StatisticalMulticenter Studies as TopicNeoplasm Recurrence, LocalNomogramsPrognosisRandomized Controlled Trials as TopicRisk FactorsSurvival RateConceptsStage III colon cancerDisease-free survivalLifestyle factorsSelf-reported dietPathologic featuresColon cancerPathologic characteristicsMultivariable Cox proportional hazards regressionCox proportional hazards regressionAdjuvant chemotherapy trialsProportional hazards regressionPredictive survivalChemotherapy trialsDFS eventsOverall survivalSurvival prediction modelHazards regressionSurvival outcomesVisual nomogramLifestyle habitsPatient outcomesCancer recurrenceLifestyle exposuresPatientsCancer
2020
Erythrocyte membrane fatty acids and breast cancer risk by tumor tissue expression of immuno-inflammatory markers and fatty acid synthase: a nested case-control study
McGee EE, Kim CH, Wang M, Spiegelman D, Stover DG, Heng YJ, Collins LC, Baker GM, Farvid MS, Schedin P, Jindal S, Tamimi RM, Eliassen AH. Erythrocyte membrane fatty acids and breast cancer risk by tumor tissue expression of immuno-inflammatory markers and fatty acid synthase: a nested case-control study. Breast Cancer Research 2020, 22: 78. PMID: 32698885, PMCID: PMC7374956, DOI: 10.1186/s13058-020-01316-4.Peer-Reviewed Original ResearchConceptsBreast cancer riskImmuno-inflammatory markersErythrocyte membrane fatty acidsCase-control studyTumor tissue expressionFatty acid synthaseCancer riskTrans fatty acidsExpression subtypesOdds ratioSpecific fatty acidsLogistic regressionHealth Study IITumor tissue blocksMembrane fatty acidsFatty acidsUnconditional logistic regressionConfidence intervalsTissue expressionT cell functionPolytomous logistic regressionAcid synthaseTumor CD4Potential confoundersTumor expression
2003
The HRAS1 variable number of tandem repeats and risk of breast cancer.
Tamimi RM, Hankinson SE, Ding S, Gagalang V, Larson GP, Spiegelman D, Colditz GA, Krontiris TG, Hunter DJ. The HRAS1 variable number of tandem repeats and risk of breast cancer. Cancer Epidemiology Biomarkers & Prevention 2003, 12: 1528-30. PMID: 14693748.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAllelesBreast NeoplasmsCase-Control StudiesDNA, NeoplasmFemaleGenes, rasGenetic Predisposition to DiseaseGenotypeHumansLogistic ModelsMiddle AgedMinisatellite RepeatsPolymerase Chain ReactionPolymorphism, GeneticProbabilityPrognosisReference ValuesRisk AssessmentSensitivity and SpecificityTandem Repeat SequencesConceptsHealth Study cohortBreast cancer casesBreast cancerCancer casesNurses' Health Study cohortIncident breast cancer casesHRAS1 VNTRHRAS1 variable numberBreast cancer riskCase-control studyGene-dose effectRare HRAS1 allelesMenopausal statusStudy cohortCancer riskOverall associationCancerHRAS1 allelesRiskRare allelesAssociationCommon allelesAllelesVariable numberCohort
2002
Weight Loss and Survival in HIV-Positive Patients in the Era of Highly Active Antiretroviral Therapy
Tang AM, Forrester J, Spiegelman D, Knox TA, Tchetgen E, Gorbach SL. Weight Loss and Survival in HIV-Positive Patients in the Era of Highly Active Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2002, 31: 230-236. PMID: 12394802, DOI: 10.1097/01.qai.0000026514.98625.8f.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapyWeight lossAntiretroviral therapyHAART useIndependent predictorsPrevious visitHighly Active Antiretroviral TherapyHealthy Living StudyCD4 cell countHIV-positive patientsHIV-positive participantsBody mass indexStrong independent predictorFurther prognostic valueProportional hazards modelBioelectrical impedance analysisFour- to sixfold increaseImportant comorbidityMass indexPrognostic valuePotential confoundersRelative riskStudy populationLiving StudyHazards model
2001
Do HIV Type 1 RNA Levels Provide Additional Prognostic Value to CD4+ T Lymphocyte Counts in Patients with Advanced HIV Type 1 Infection?
Arduino J, Fischl M, Stanley K, Collier A, Spiegelman D. Do HIV Type 1 RNA Levels Provide Additional Prognostic Value to CD4+ T Lymphocyte Counts in Patients with Advanced HIV Type 1 Infection? AIDS Research And Human Retroviruses 2001, 17: 1099-1105. PMID: 11522179, DOI: 10.1089/088922201316912709.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsHIV-1 disease progressionBaseline HIV-1 RNA levelsT-lymphocyte countsT lymphocytesDisease progressionLymphocyte countRNA levelsCells/Prognostic informationHigh baseline HIV-1 RNA levelsHIV type 1 RNA levelsPlasma HIV-1 RNA levelsSubsequent HIV-1 disease progressionAdvanced HIV-1 diseaseHIV Type 1 InfectionConditional logistic regression analysisDisease progression independentHIV-1 diseaseAdditional prognostic informationAdditional prognostic valueType 1 infectionCase-control studyLogistic regression analysisClinical status
1997
Glutathione S-transferase class mu deletion polymorphism and breast cancer: results from prevalent versus incident cases.
Kelsey KT, Hankinson SE, Colditz GA, Springer K, Garcia-Closas M, Spiegelman D, Manson JE, Garland M, Stampfer MJ, Willett WC, Speizer FE, Hunter DJ. Glutathione S-transferase class mu deletion polymorphism and breast cancer: results from prevalent versus incident cases. Cancer Epidemiology Biomarkers & Prevention 1997, 6: 511-5. PMID: 9232338.Peer-Reviewed Original ResearchConceptsBreast cancerGene deletion polymorphismCase seriesDeletion polymorphismHealth StudyNull genotypeGSTM1 deletionGlutathione S-transferase class muPrevalent breast cancerIncident breast cancerNurses' Health StudyGSTM1 gene deletion polymorphismBreast cancer riskDuration of survivalAge-matched controlsGSTM1 null genotypeBreast cancer prognosisMolecular epidemiologic studiesImproved survivalCigarette smokingIncident casesOdds ratioPrevalent casesEpidemiologic studiesCancer risk
1989
Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients.
Spiegelman D, Maurer LH, Ware JH, Perry MC, Chahinian AP, Comis R, Eaton W, Zimmer B, Green M. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. Journal Of Clinical Oncology 1989, 7: 344-54. PMID: 2537384, DOI: 10.1200/jco.1989.7.3.344.Peer-Reviewed Original ResearchConceptsLong-term survivalPerformance statusOverall survivalPrognostic factorsED patientsMetastatic sitesLung cancerExtensive small cell lung cancerResponse rateSmall cell lung cancerFailure-free survivalOverall objective responseLead-time biasLeukemia Group BPretreatment prognostic factorsSmall cell carcinomaLung cancer stagingImproved response ratesPercentage of womenObjective responseSupraclavicular lymphPatient populationLD patientsCancer stagingFemale gender